Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology.

Abstract

Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder engendered by transcriptional silencing of the fragile X messenger ribonucleoprotein 1 (<i>FMR1</i>) gene. Given the early onset of behavioral and molecular changes, it is imperative to know the optimal timing for therapeutic intervention. Case reports documented benefits of metformin treatment in FXS children between 2 and 14 y old. In this study, we administered metformin from birth to <i>Fmr1^-/y</i> mice which corrected up-regulated mitogen-2 activated protein kinase/extracellular signal-regulated kinase and mammalian/mechanistic target of rapamycin complex 1 signaling pathways and specific synaptic mRNA-binding targets of FMRP. Metformin rescued increased number of calls in ultrasonic vocalization and repetitive behavior in <i>Fmr1^-/y</i> mice. Our findings demonstrate that in mice, early-in-life metformin intervention is effective in treating FXS pathophysiology.